[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337022-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337022-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-the-function-and-prognostic-value-of-rplp0-rplp1-and-rplp2-expression-in-lung-adenocarcinoma","Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma","","Lung adenocarcinoma (LUAD) is the most common non-small cell lung cancer subtype and is marked by heterogeneity and poor clinical outcomes. Ribosomal proteins RPLP0, RPLP1, and RPLP2 have been linked to multiple cancers, yet their roles and prognostic relevance in LUAD remain unclear. This study applies comprehensive bioinformatic analyses to evaluate expression, genomic alterations, promoter methylation, survival outcomes, and immune infiltration. Results show overexpression of RPLP0/RPLP1/RPLP2 in LUAD, associated with copy number variation and reduced promoter methylation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-the-function-and-prognostic-value-of-rplp0-rplp1-and-rplp2-expression-in-lung-adenocarcinoma/337022/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-the-function-and-prognostic-value-of-rplp0-rplp1-and-rplp2-expression-in-lung-adenocarcinoma/337022.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study in LUAD?","Question",{"text":63,"@type":64},"To determine how the expression of RPLP0, RPLP1, and RPLP2 functions in lung adenocarcinoma and whether these genes are associated with patients’ prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What relationship was found between RPLP0/RPLP1/RPLP2 expression and patient outcomes?",{"text":68,"@type":64},"Higher expression of RPLP0, RPLP1, or RPLP2 was associated with worse clinical outcomes, including overall survival (OS), first progression (FP), and post-progression survival (PPS).",{"name":70,"@type":61,"acceptedAnswer":71},"Which mechanisms and downstream factors did the study evaluate?",{"text":72,"@type":64},"It assessed copy number variation and promoter methylation to explain altered expression, examined how RPLP expression correlates with immune cell infiltration, and screened existing drugs that may inhibit RPLP1 and RPLP2 expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337022,1790178440,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Molecular Histology (2024) 55:1079–1091 [https://doi.org/10.1007/s10735-024-10251-z](https://doi.org/10.1007/s10735-024-10251-z)  \nORIGINAL PAPER  \nExploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma  \nChunyan Xu1 · Zhimin Lu2 · Guoxin Hou3 · Moran Zhu1  \nReceived: 15 July 2024 / Accepted: 20 August 2024 / Published online: 29 August 2024 © The Author(s) 2024  \nAbstract  \nLung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and is characterized by its heterogeneity and poor prognosis. The role of ribosomal proteins RPLP0, RPLP1 and RPLP2 in multiple cancers has been implicated. However, their function in LUAD and their correlation with the poor prognosis of LUAD remains elusive. In this study, we performed a comprehensive bioinformatic analysis of the impact of these ribosomal proteins on LUAD. Our findings reveal that RPLP0, RPLP1 and RPLP2 are overexpressed in LUAD, which are likely attributed to abnormal copy number variations and decreased methylation levels of their promoters. LUAD patients with high expression of RPLP0, RPLP1 or RPLP2 have worse clinical outcomes in terms of overall survival (OS), first progression (FP) and post-progression survival (PPS), indicating poor prognosis. Moreover, the expression of RPLP0, RPLP1 and RPLP2 affects immune cell infiltration in LUAD tissues. Finally, we identified multiple existing drugs that may inhibit the expression of RPLP1 and RPLP2 . Collectively, our data implicate the oncogenic role of RPLP0, RPLP1 and RPLP2 in LUAD and underscore their prognostic value in LUAD patients.  \nKeywords Lung adenocarcinoma · RPLP0 · RPLP1 · RPLP2 · Prognosis · Immune infiltration  \nIntroduction  \nLung cancer is the leading cause of cancer-related deaths worldwide, accounting for approximately 25% of all cancer fatalities (Brody 2020; Nasim et al. 2019). Lung cancers can be classified into two main types: non-small cell lung cancer  \nChunyan Xu and Zhimin Lu contributed equally to this work.  \n􀀍 Guoxin Hou [gxhou91@163.com](gxhou91@163.com)  \n􀀍 Moran Zhu [zmr2355@163.com](zmr2355@163.com)  \n1 Department of Pulmonary and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong, Shanghai, China  \n2 Department of Outpatient, The Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China  \n3 Department of Oncology, The Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China  \n(NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most prevalent, comprising about 85% of all cases (Chen et al. 2014) . Within NSCLC, lung adenocarcinoma (LUAD) is the most common subtype, occurring frequently among non-smokers (Ma et al. 2023; Yang et al. 2020) . Despite advancements in early detection and targeted therapies, the prognosis for LUAD remains poor due to its high potential for recurrence, metastasis, and drug resistance (Schenk et al. 2020; Uprety et al. 2024) . Therefore, a more comprehensive understanding of the molecular mechanisms underlying LUAD tumorigenesis and progression, exploring the target molecules associated with poor prognosis of LUAD is crucial for developing more effective diagnostic and therapeutic strategies.  \nRibosomal proteins play essential roles in protein synthesis by forming the core structural and functional components of ribosomes. Among these, the ribosomal P complex, formed by RPLP0, RPLP1 and RPLP2, is a key component of the ribosomal stalk, which is crucial for the interaction between ribosomes and translation factors during protein synthesis (Artero-Castro et al. 2015) . Recent studies have indicated that RPLP0, RPLP1 and RPLP2 play essential roles in a various type of cancer development and  \nprogression (Artero-Castro et al. 2011a, b) . For instance, RPLP0 has been associated with prostate cancer (PérezGómez et al. 2023), in","cbCair6Xbb2FHXkU","https://ap.wps.com/l/cbCair6Xbb2FHXkU","pdf",2603345,13,"English","# Abstract\n# Introduction\n## Background on LUAD and prognosis\n## Ribosomal P complex and prior cancer evidence\n# Study approach\n## Expression and survival analyses\n## Copy number variation and promoter methylation\n## Immune infiltration and drug screening","[{\"question\":\"What was the main goal of this study in LUAD?\",\"answer\":\"To determine how the expression of RPLP0, RPLP1, and RPLP2 functions in lung adenocarcinoma and whether these genes are associated with patients’ prognosis.\"},{\"question\":\"What relationship was found between RPLP0/RPLP1/RPLP2 expression and patient outcomes?\",\"answer\":\"Higher expression of RPLP0, RPLP1, or RPLP2 was associated with worse clinical outcomes, including overall survival (OS), first progression (FP), and post-progression survival (PPS).\"},{\"question\":\"Which mechanisms and downstream factors did the study evaluate?\",\"answer\":\"It assessed copy number variation and promoter methylation to explain altered expression, examined how RPLP expression correlates with immune cell infiltration, and screened existing drugs that may inhibit RPLP1 and RPLP2 expression.\"}]","Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma | PDF",1790017424,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8affb8184b7046965732b1f5e6ac4191.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d540921a3e14ef668059b41fdecc7697.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc26a0aa3c74430ca9cf1f5520a12fd3.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f5db978b01b6a17291ece2ab9e8dc56.webp",980,1301]